CIRC subsidiary China National Nuclear Corporation Haidewei submits IND application for BNCT boron drug

AASTOCKS
2025.10.19 11:57

China National Nuclear Corporation (01763.HK) announced that the information on the official website of the National Medical Products Administration's drug review center shows that the company's subsidiary, China Nuclear Haidewei, has publicly accepted the application for "Injectable Boron [10B] Phenylalanine."

The "Injectable Boron [10B] Phenylalanine" under research by China Nuclear Haidewei has significant clinical advantages for tumors that are insensitive to radiotherapy and chemotherapy, recurrent, refractory, infiltrative, in the middle to late stages, and locally metastatic. It has a short treatment course, low toxic side effects, and integrates diagnosis and treatment, representing the development direction and cutting-edge innovation of modern precision oncology

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer